Protozoan parasites of the genus Leishmania generate severe human diseases termed Leishmaniases. Due to their frequency and the severity of certain clinical forms, these diseases represent a major public health problem and limit the economic growth in various developing countries.
Chemotherapy remains the most important element in the control of VL as there are currently no vaccines to prevent VL infection. All current treatments suffer from significant drawbacks, i.e. parenteral route of administration, length of treatment (21 to 28 days), toxicity, or/and cost which limits their utilisation in disease endemic areas.